Going Beyond the Grand Mean: Subgroup Analysis in Meta-Analysis of Randomised Trials

Systematic Reviews in Health Care: Meta-Analysis in Context: Second Edition

Volumn , Issue , 2008, Pages 143-156

  Smith, George Davey ^a   Egger, Matthias ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Meta analysis; Meta analytic subgroup; Patient data; Randomised trials; Subgroup analysis

Indexed keywords

EID: 84899840245     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470693926.ch8     Document Type: Chapter

References (39)

1. Wittes RE. Problems in the medical interpretation of overviews. Stat Med 1987;6:269-76.
2. Davey Smith G, Egger M. Incommunicable knowledge? Interpreting and applying the results of clinical trials and meta-analyses. J Clin Epidemiol 1998;51:289-95.
3. The European Infarction Study Group. European Infarction Study (EIS). A secondary prevention study with slow release oxprenolol after myocardial infarction: morbidiy and mortality. Eur Heart J 1984;5:189-202.
4. Efron B, Morris C. Stein's paradox in statistics. Sci Am 1977;236:119-27.
5. Oxman AD, Guyatt GH. A consumer's guide to subgroup analyses. Ann Intern Med 1992;116 :78-84.
6. Yusuf S, Wittes J, Probstfield J, Tyroler HA. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA 1991;266:93-8.
7. The Beta-Blocker Pooling Project Research Group. The Beta-Blocker Pooling Project (BBPP): subgroup findings from randomized trials in post infarction patients. Eur Heart J 1988; 9:8-16.
8. Ingelfinger JA, Mosteller F, Thibodeau LA, Ware JH. Biostatistics in clinical medicine. New York: McGraw, 1994.
9. Peto R. Statistical aspects of cancer trials. In: Halnan KE, ed. Treatment of cancer. London: Chapman and Hall, 1982.
10. Buyse ME. Analysis of clinical trial outcomes: some comments on subgroup analyses. Contr Clin Trials 1989;10:187S-94S.
11. Mauri F, Gasparini M, Barbonaglia L, et al. Prognostic significance of the extent of myocardial injury in acute myocardial infarction treated by streptokinase (the GISSI trial). Am J Cardiol 1989;63:1291-5.
12. Peto R. Misleading subgroup analysis in GISSI. Am J Cardiol 1990;64:771.
13. Schroeder R. Oxprenolol in myocardial infarction survivors: brief review of the European Infarction Study results in the light of other beta-blocker post infarction trials. Z Kardiol 1985;74 (suppl 6):165-72.
14. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985;17:335-71.
15. Peto R. Why do we need systematic overviews of randomized trials. Stat Med 1987;6:233-40.
16. Freemantle N, Cleland J, Young P, Mason J, Harrison J. Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999;318:1730-7.
17. Davey Smith G, Song F, Sheldon TA. Cholesterol lowering and mortality: the importance of considering initial level of risk. BMJ 1993;306:1367-73.
18. Bailey K. Generalizing the results of randomized clinical trials. Contr Clin Trials 1994;15:15-23.
19. Holme I. Relationship between total mortality and cholesterol reduction as found by meta-regression analysis of randomized cholesterol lowering trials. Contr Clin Trials 1996;17:13-22.
20. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994;343:311-22.
21. Zelen M. Intravenous streptokinase for acute myocardial infarction. N Engl J Med 1983;308:593.
22. Davey Smith G. Low blood cholesterol and non-atherosclerotic disease mortality: where do we stand? Eur J Cardiol 1997;18:6-9.
23. Davey Smith G, Egger M. Who benefits from medical interventions? Treating low risk patients can be a high risk strategy. BMJ 1994;308:72-4.
24. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
25. Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebocontrolled trial. N Engl J Med 1987;317:185-91.
26. Egger M, Neaton JD, Phillips AN, Davey Smith G. Concorde trial of immediate versus deferred zidovudine. Lancet 1994;343:1355.
27. Egger M, Davey Smith G. Risks and benefits of treating mild hypertension: a misleading meta-analysis? J Hypertens 1995;13:813-15.
28. Sharp SJ, Thompson SG, Altman D. The relation between treatment benefit and underlying risk in meta-analysis. BMJ 1996;313:735-8.
29. Thompson SG, Smith TC, Sharp SJ. Investigating underlying risk as a source of heterogeneity in meta-analysis. Stat Med 1997;16:2741-58.
30. Hoes AW, Grobbee DE, Lubsen J. Does drug treatment improve survival? Reconciling the trials in mild-to-moderate hypertension. J Hypertens 1995;13:805-11.
31. L'Abbé KA, Detsky AS, O'Rourke K. Meta-analysis in clinical research. Ann Intern Med 1987;107:224-33.
32. Song F. Exploring heterogeneity in meta-analysis: is the L'Abbé plot useful? J Clin Epidemiol 1999;52:725-30.
33. Eccles M, Freemantle N, Mason J. North of England evidence based development project: guideline for angiotensin converting enzyme inhibitors in primary care management of adults with symptomatic heart failure. BMJ 1998;316:1369-75.
34. Garg R, Yusuf S. for the Collaborative Group on ACE Inhibitor Trials. Overview of randomised trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995;273:1450-6.
35. Yusuf S, Zucker D, Peduzzi P, et al. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Graft Surgery Trialists Collaboration. Lancet 1994;344:563-70.
36. Takaro T, Hultgren HN, Lipton MJ, Detre KM. The VA cooperative randomised study of surgery for coronary arterial occlusive disease II: Subgroup with significant left main lesions. Circulation 1976;54 (suppl 3):107-17.
37. Phillips AN, Davey Smith G. How independent are "independent" effects? Relative risk estimation when correlated exposures are measured imprecisely. J Clin Epidemiol 1991;44:1223-31.
38. Davey Smith G, Phillips AN. Confounding in epidemiological studies: why "independent" effects may not be all they seem. BMJ 1992;305:757-9.
39. Davey Smith G, Egger M, Phillips AN. Meta-analysis: beyond the grand mean? BMJ 1997; 315:1610-14.